- Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-NaÏve, High-Risk Non-Muscle Invasive Bladder Cancer
- January 10, 2025
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- January 06, 2025
- U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
- December 20, 2024
- Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
- December 19, 2024
- Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
- December 17, 2024
- Pfizer Declares First-Quarter 2025 Dividend
- December 12, 2024
- Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
- December 12, 2024
- Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
- December 10, 2024
- Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
- December 10, 2024
- Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
- December 05, 2024
- Pfizer Announces New Chief Scientific Officer and President, Research & Development
- November 20, 2024
- European Commission Approves Pfizer's HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
- November 20, 2024
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- November 14, 2024
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- November 04, 2024
- Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
- October 29, 2024
- Advisory Committee on Immunization Practices Recommends PREVNAR® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
- October 23, 2024
- U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
- October 22, 2024
- Tim Buckley Elected to Pfizer's Board of Directors
- October 15, 2024
- U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
- October 11, 2024
- Pfizer's TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Triald
- October 10, 2024
- Pfizer Declares Fourth-Quarter 2024 Dividend
- October 09, 2024
- Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
- October 08, 2024
- Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
- September 25, 2024
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
- September 20, 2024
- Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
- September 17, 2024
- Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexi
- September 14, 2024
- Pfizer's BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
- September 14, 2024
- Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
- September 11, 2024
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
- August 28, 2024
- Pfizer Launches PfizerForAllTM, a Digital Platform that Helps Simplify Access to Healthcare
- August 27, 2024
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
- August 22, 2024
- Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
- August 16, 2024
- Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
- August 12, 2024
- Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
- July 30, 2024
- European Commission Approves Pfizer's DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
- July 25, 2024
- Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate
- July 24, 2024
- Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron
- July 11, 2024
- Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development
- July 09, 2024
- Cyrus Taraporevala Elected to Pfizer's Board of Directors
- July 01, 2024
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
- June 27, 2024
- Pfizer Declares Third-Quarter 2024 Dividend
- June 26, 2024
- Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts
- June 18, 2024
- ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
- June 16, 2024
- Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
- June 14, 2024
- Pfizer's ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- June 01, 2024
- Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
- June 01, 2024
- Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
- May 31, 2024